Clay Siegall’s Role In Targeted Cancer Therapies

The fight against cancer is nothing to take lightly. Each and every year, thousands of people are diagnosed with some form of this disease. The disease can manifest from many different organs in the body such as the lungs and liver. Fortunately, this is the 21st century and some of the most advanced cancer fighting medications are on the market. Antibody-based conjugates are at the top of the list thanks to their progressive and efficient characteristics. These powerful medications are designed to attach themselves to cancer cells and then deliver a cell-killing blow. All of this is done without ever harming any of the good cells.

Dr. Clay Siegall, CEO and president of Seattle Genetics, is one of the best in the business when it comes to this subject. Siegall is a man of many talents as he’s known to be a scientist, a doctor, a mentor, a motivational speaker, an entrepreneur and a businessman. This guy’s educational background is immense as well as respected as he has a Ph.D in Genetics and a B.S. in Zoology. Siegall is basically a product of the prestigious George Washington University and the University of Maryland. Seattle Genetics is by far the worldwide leader in antibody-based therapies. This company was co-founded by Dr. Siegall himself in 1998. It specializes in developing and commercializing state-of-the-art cancer medications. Located in Bothell, Washington, this biotech oncology organization has nearly 1,000 employees, it’s one of the biggest job producers in the Puget Sound region, and it was visited in 2016 by former-Vice President Joe Biden.

Rigorous research, drug development and scientific innovation is the name of the game as Seattle Genetics perfectly personifies this notion. Thousands of lives have been saved and the medications have helped to create a better quality of life overall. All in all, Dr. Clay Siegall is one of the most important figures in cancer research, and his extraordinary resume is a true testament of it all.